West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. makes the small, unglamorous parts without which almost no injectable medicine can reach a patient: the elastomer stoppers, seals and plungers, the coated and washed "high-value" components, the vials, syringes and cartridges, and the self-injection devices that hold and deliver a drug. It is the largest supplier of primary containment in the injectable drug industry, with roughly $3.07 billion of net sales in fiscal 2025 and about 10,800 employees, and it earns the great majority of its profit from a part of the market that its customers cannot easily re-source.

This is a story about a moat that is bureaucratic rather than technological. A rubber stopper is not a hard thing to make; a rubber stopper that has been qualified into a specific drug's regulatory filing, and that a pharmaceutical company would have to re-test and re-file to replace, is very hard to make — and switching away from it is expensive enough that customers mostly do not. West's growth has come from pushing customers up its product ladder into those qualified, higher-priced, higher-margin components, a mix shift that accelerated through 2025 and the first half of 2026. The file turns on whether that upgrade cycle is a durable, decade-long tailwind or a cyclical rebound dressed up as a structural story — and on whether West's incoming chief executive can keep the compounding going while the company's largest end-market, GLP-1 obesity drugs, faces its first real test from oral alternatives.